DOI: 10.1002/ejic.201((will be filled in by the editorial staff))

Photoactivated functionizable tetracarbonyl phenylpyridine manganese(I) complexes as CO-releasing molecules (CO-RMs): a direct Suzuki–Miyaura cross-coupling on a thermally-stable CO-RM

Jonathan S. Ward[], Joshua T. W. Bray[], Benjamin J. Aucott[a], Conrad Wagner, James W. B. Moir[b], Jason M. Lynam\*[a] and Ian J. S. Fairlamb\*[]

**Keywords:** Carbon monoxide/CO-RM/irradiation/morpholine\Suzuki-Miyaura

|  |
| --- |
| Over recent years, many carbon monoxide-releasing molecules (CO-RMs) have been developed as a means of delivering CO in biological systems for use as a therapeutic molecule. A new class of CO-RMs are reported based on a previously known tetracarbonyl phenylpyridine manganese(I) motif. A pre-functionalized CO-RM undergoes a direct Pd-catalysed Suzuki–Miyaura cross-coupling with phenylboronic acid to give a π-extended three-ring CO-RM. Cross-coupling conditions were modified to allow coupling of a morpholine containing boronic acid on to a CO-RM, introducing drug-like functionality. An LED system was used to facilitate controlled CO-release. Irradiation using an LED (400 nm) gives rise to faster CO-release with lower overall input power compared to traditional use of a TLC lamp (365 nm). |

Introduction

The interest in carbon monoxide (CO) as a therapeutic molecule has increased significantly over the past 10 years. This is because of studies showing a wide variety of therapeutic benefits.[1-3](#_ENREF_1) This ranges from increased healing rates and vasodilation, to inhibition of bacterial growth.[4-6](#_ENREF_4) The multiple benefits that carbon monoxide-releasing molecules (CO-RMs) could potentially give present a large advantage over traditional organic drugs, which may only treat one condition and involve a single binding site. A single CO-RM has the potential to treat a variety of ailments rather than needing a complex mixture of different drugs.

CO-RMs may be thought of as a pro-drug, *i.e.* a means of delivering the CO to a biological target. This typically requires a transition metal carbonyl complex stabilised by a multidentate ligand.[7](#_ENREF_7) The selection of a readily accessible, functionalisable ligand therefore provides a modular approach for the synthesis of a large range of analogues. Importantly, the installation of synthetic handles onto the ligand allow for late stage functionalisation to be carried out, the thermal sensitivity of the ‘Mn(CO)4’­ motif require very mild conditions to prevent degradation.

CO-RMs require a method of activation and there are three key ways this can be done. The first is thermally-enabled by designing a molecule that releases CO when in solution.[8](#_ENREF_8) Previously reported iron(0) tricarbonyl complexes release CO quickly on dissociation of the norbornadiene ligand in solution without the need of a target such as myoglobin. This presents some advantages, such as definitely getting CO-release from the molecule on addition. The problem is that the CO-release rate is fixed at a given concentration, and CO release begins immediately and could be fully released before reaching the desired target. However with careful ligand tuning, optimal CO release rates could still be obtained.

\_\_\_\_\_\_\_\_\_\_\_\_

[a] Department of Chemistry, University of York, Heslington, York, YO10 5DD  
Fax: +44 (0) 1904 322516  
E-mail: [ian.fairlamb@york.ac.uk](mailto:ian.fairlamb@york.ac.uk), jason.lynam@york.ac.uk  
Homepage: www.york.ac.uk/chemistry

[b] Department of Biology, University of York, YO10 5DD.

Supporting information for this article is available on the WWW under http://www.eurjic.org/ or from the author.

The second method of CO-RM activation is by a chemical trigger such as an enzyme.[9](#_ENREF_9) [Mn(CO)4(S2CNMe(CH2CO2H))], a CO-RM developed by Mann and co-workers is stable in phosphate buffered saline for several hours[10](#_ENREF_10) however, in the presence of myoglobin, CO is rapidly released from the CO-RM to a binding site. This could be problematic as CO-release could be similarly initiated by other proteins – a specific protein-inducing CO-release event is unlikely and only the heme oxygenases (HO-1 and HO-2) are able to achieve this. Enzyme-triggered CO-RMs have the advantage of definitely inducing CO-release if a known target/enzyme is present.

The final method of CO-RM activation is by photochemical irradiation. There are several known photoCO-RM classes in the literature.[11-18](#_ENREF_11) PhotoCO-RMs do not degrade significantly over a short period of time, either thermally or in the presence of a CO binder such as myoglobin. Employing light to activate a CO-RM provides exquisite control of the CO-release kinetics. The light intensity and CO-RM concentration can be varied, and clearly for use in tissue longer wavelengths are needed (> 550 nm). Other applications for CO-RMs (*e.g.* skin treatments) would in theory allow lower wavelengths to be used (~400 nm).

This paper reports the development of photoactivated CO-RMs, based on a tetracarbonyl phenylpyridine manganese(I) scaffold. The parent non-functionalised compound prepared by Bruce and co‑workers has been expanded here to include a series of substituents.[19](#_ENREF_19) These were prepared to assess how ligand structural changes affect the ability of the ‘Mn(CO)4’­ motif to release CO.

An LED irradiation system has been developed which can deliver controlled light emission to CO-RM samples over a narrow wavelength range using high quality LEDs.[14](#_ENREF_14) The system can monitor the current drawn from the LED so that the same light intensity can be used in repeat experiments. The light intensity, wavelength, and duration of irradiation are as important as any typical reaction condition, such as temperature.

The CO-RMs reported in this paper release efficiently using a 400 nm LED, emitting light with a longer wavelength than a common benchtop TLC lamp (365 nm).[13](#_ENREF_13)

**Results and Discussion**

Initial experiments were used to establish if the tetracarbonyl phenylpyridine manganese(I) complex would be a strong candidate for further functionalisation, by preparing a series of complexes with varying substituents in the 4-position of the phenyl ring. This position was chosen so that attached groups would not sterically interfere with the manganese(I) centre, or give isomers when reacted with BnMn(CO)5. A series of Suzuki–Miyaura cross-couplings were used to prepare suitable 2-aryl-pyridine ligands for use in the cyclometallation reactions (Scheme 1), the conditions and outlined in Table 1.



**Scheme 1.** General reaction scheme for the preparation of substituted phenyl pyridine ligands; R =H (**1a**), F (**1b**), Cl (**1c**), Br (**1d**), Ph (**1e**). Compound **1a** is commercially available.

**Table 1.** Synthesis details for ligands **1b-e**.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entry | R | Catalyst | Base | % Yield |
| **1b** | F | AB cat (0.7 mol %) | Na2CO3(aq) | 79 |
| **1c** | Cl | Pd(PPh3)4 (2 mol %) | K2CO3(aq) | 83 |
| **1d**  **1e** | Br  Ph | Pd(PPh3)4 (2 mol %)  Pd(PPh3)4 (2 mol %) | Na2CO3(aq)  Na2CO3(aq) | 59  59 |

The 2-arylpyridines were prepared in good yields using cross-coupling conditions given in Table 1. For compounds **1c**-**1e**, Pd(PPh3)4 was used as the catalyst. For fluorinated compound **1b** an alternative di-nuclear pyridyl-bridged palladium catalyst was used.[20](#_ENREF_20) The 2-arylpyridines were then used in a cyclometallation reaction with BnMn(CO)5, an efficient reagent for the addition of a manganese tetracarbonyl group to phenylpyridine.[21](#_ENREF_21) This results in the formation of complexes **2a**-**2e**; the details of preparation and yields are shown in Scheme 2 and Table 2.



**Scheme 2.** General reaction scheme for the preparation of CO‑RMs **2a-e**. (R = H, F, Cl, Br, Ph).

**Table 2.** Yields obtained for complexes **2a-e**.

|  |  |  |
| --- | --- | --- |
| Entry | R | % Yield |
| **2a**  **2b** | H  F | 88  43 |
| **2c** | Cl | 83 |
| **2d**  **2e** | Br  Ph | 72  72 |

The manganese(I) complexes were isolated in moderate to excellent yields, following a simple filtration of the solid products. Further purification by column chromatography on silica-gel could be performed if required. Due to a slower rate of reaction in the synthesis of **2b** a further 0.2 equivalents of BnMn(CO)5 was needed to ensure that a pure product was obtained.

Crystals of **2c** and **2d** were obtained by layering CH2Cl2 solutions with *n*-hexane. Crystals of BnMn(CO)5 have also been obtained by sublimation. The three structures have been confirmed by X-ray crystallography, and all details are shown in the supplementary information. By way of an exemplar complex, the X-ray structure for complex **2d** is shown in Figure 1. It is interesting to note the C(14)-Mn(1)-C(12) bond angle of 168.51(8) ° is quite distorted from an ideal octahedron. This is due to the size of the phenylpyridine system, which forces the system to change geometry giving a N‑Mn‑C(11) bond angle of only 79.55(6) °. This geometry could play an important role in the determining the properties of the CO-RM. The slight distortion could alter how electron density passes from the ligand to the metal, potentially altering the mode of CO-release.






Figure 1. X-ray crystal structure of complex **2d**. Atoms displayed as ellipsoids at 50% probability. Hydrogen atoms have been omitted for clarity. Crystallised from CH2Cl2/hexane. Selected bond angles (°) and distances (Å): Mn(1)-C(11) = 2.0477(17) , Mn(1)-N(1) = 2.0638(14), Mn(1)-C(15) = 1.8007(18), Mn(1)-C(12) = 1.8642(19), Mn(1)-C(13) = 1.8401(19), Mn(1)-C(14) = 1.8544(19); C(14)-Mn(1)-C(12) = 168.51(8), C(13)-Mn(1)-C(12) = 95.58(8),C(11)-Mn(1)-C(15) = 93.25(7), C(13)-Mn(1)-N(1) =96.04(7), C(15)-Mn(1)-N(1) = 172.80(7), C(14)-Mn(1)-N(1) =90.03(7) , C(12)-Mn(1)-N(1) =88.03(7), N(1)-Mn(1)-C(11) = 79.55(6).

**Myoglobin assay: determination of CO-release rates.**

To assess how complexes **2a-e** release carbon monoxide, a myoglobin assay in phosphate buffered saline was carried out. The assay was left in the dark for an initial period of 45 mins in order to ascertain if the compounds are stable in the absence of light and in the presence of sodium dithionite and myoglobin. Figure 2 shows the CO release profiles for complex **2a-e** using a conventional UV lamp (365 nm) placed above the sample for irradiation.



**Figure 2.** CO release from 10 µM **2a** and **2e** (left) and **2b-d** (right) using 50-60 µM myoglobin in a myoglobin assay. Irradiation with 365 nm TLC lamp. On for 2 min in a 5 min period. \* indicates the start of irradiation cycles.

These CO-RMs do not release any significant quantity of CO over a period of 45 minutes in the dark, even on the addition of sodium dithionite. However, following the onset of irradition CO release was observed. Complexes **2a** and **2e** have a similar initial rate of CO release. With irradiation of 40 µM CO-RM, 50 µM myoglobin is saturated with CO. It is evident that the addition of a phenyl group to the parent compound **2a** does not significantly alter the CO-releasing properties of the compound. This is a desirable feature as the structure can be changed and the kinetics of CO release controlled by varying light intensity.

Comparing the halogen-substituted complexes **2b-d**, chloro complex **2c** initially releases slower than the other two complexes. The half lives of each complex have been calculated from the data in Figure 2 (Table 3). There does not appear to be a direct relationship between half-life and the molar adsoprtion coefficient (Table 3) implying that the difference in CO-release is not simply a function of the efficiency of absorption by the complexes.

**Table 3.** Half-life CO-release values for complexes **2a-e**, with irradiation at 365 nm using a benchtop TLC lamp.



|  |  |  |  |
| --- | --- | --- | --- |
| Entry | R | t½ / mins | **e at 300 nm / mol-1 dm-3 cm-1** |
| **2a**  **2b** | H  F | 23  17 | **4054 4522** |
| **2c** | Cl | 27 | **4534** |
| **2d**  **2e** | Br  Ph | 18  30 | **4872**  **13166** |

Complex **2b** has the fastest t½ value of 17 mins but is comparable with complex **2d** at 18 minutes. The amount of irradiation recieved in these experiments is 40% of the total time (2 mins on, 3 mins off), so theoretically the amount of irradiation required makes these times much shorter.

It is important to mention that the variation in these results comes from using a TLC lamp to irradiate the samples, leading us to exploit an LED system for all subsequent experiments.



Complexes **2c** and 2**d** were taken forward. The CO-RMs were used at concentrations of 10 and 40 µM using a 400 nm narrow-band LED drawing a power of 2.4 W. This was attached directly to the UV-vis cuvette so that a high percentage of light passes through the sample, unlike the conventional method of using a TLC lamp in which the bulb is too large to fit close to the cuvette. Full details about the LED system have been reported previously.[14](#_ENREF_14)

Figure 3 shows a comparison of the 40µM CO-RM myoglobin assays for complexes **2c** and **d** when an LED and a TLC lamp is used for irradiation.



**Figure 3.** CO release from 40 µM CO-RM 2c(left) and 2d (right) using 50-60 µM myoglobin. Irradiation with 365 nm TLC lamp and LED (400 nm, 2.4 W). On for 2m per 5m period. \* indicates start of irradiation cycles. 0-35 minutes omitted for clarity as it stays close to 0 throughout this period. Spline curves are added as a guide.

Irradiation from an LED is found to be significantly more efficient at the same concentration compared with use of the TLC lamp. This is especially the case for complex **2c** where the myoglobin is saturated with CO 25 mins before the same experiment with a TLC lamp. With the use of an LED, the *t*½ value of complex **2c** is reached within 2 mins of irradiation. Given that the input power of the LED is 2.4 W and that the input power of the TLC used was 6 W, these data demonstrate the true efficency of the LED system. Figure 4 shows the UV-vis spectrum for complex **2d** in MeCN, in addition to the clean deoxy- to carboxy-myoglobin conversion following irradiation by LED.




**Figure 4.** UV spectrum in MeCN at 1.125×10−4 mol dm−3 for CO‑RM **2d** (left) and full spectral conversion from deoxy-Mb to carboxy‑Mb (right) using 40 µM **2d** (spectra used to calculate the CO profile curve shown, right).

The UV-vis spectrum in Figure 4 shows that complex **2e** has a weak absorbance at 400 nm. The 400 nm LED has a spectral width of ± 20 nm. Nevertheless, rapid conversion from deoxy-Mb to carboxy‑Mb is observed within minutes. It is also faster than using the TLC lamp. It is important to note that the LED light is being absorbed at a wavelength with a lower absorption coefficient compared with 365 nm, emphasising the CO-release efficiency of these manganese(I) complexes on photoirradiation.

Another myoglobin assay was also carried out with complexes **2c** and **2d** to assess how many molecules of CO were released per molecule of CO-RM. Figure 5 shows the 10 µM CO release profile for complexes **2c** and **d**.

Figure 5 shows that complexes **2c** and **2d** release almost three molecules of CO per molecule of CO-RM. This is advantageous compared to many CO-RMs in the literature as a lower concentration of CO-RM is required to get the same amount of CO released.[22](#_ENREF_22) This could dramatically reduce side effects if a drug can be used at lower concentrations. **2d** releases faster than **2c** at 10 µM which tallies well with the 40 µM TLC lamp irradiation studies. The kinetic curves are smoother with the automatically-timed LED system, which is a further advantage.



**Figure 5.** CO release from 10µM 2c+d using 50-60 µM myoglobin. Irradiation with LED (400 nm, 2.4 W). On for 2m per 5m period. \*indicates start of irradiation cycles.

CO-RMs **2c** and **2d** contain an aryl halide motif, providing an opportunity to directly functionalise these CO-RMs and alter their properties. Highly electrophilic η-5/6 metal (Cr/Mn/Fe) tricarbonyl fragments have previously been used to activate aryl-halides to the oxidative addition of Pd into C‑X bonds and to facilitate cross-coupling.[23](#_ENREF_23), [24](#_ENREF_24) So as a proof of concept **2e** was synthesised via a Pd‑catalysed Suzuki–Miyaura cross-coupling reaction of **2d** with phenylboronic acid.[25](#_ENREF_25) The optimized conditions are shown in Scheme 3.



Scheme 3. Direct Suzuki–Miyaura cross-coupling on **2d** to give arylated product **2e**.

The product **2e** was isolated in 67 % yield following chromatography on silica-gel. The product **2e** has been previously prepared by cyclometallation (Scheme 1) and comparison of 1H and 13C NMR, IR and LIFDI-MS data with the original reported synthesis confirm the presence of cross coupled product 1e *via* a different route. Crucially the conditions employed here operate at 50 °C lower than those previously reported (100 °C)[25](#_ENREF_25) as above 70 °C, **2e** suffers from considerable degradation.

Application of the previously developed conditions (Scheme 3) to a more challenging boronic acid (**3**) with **2d** however failed to provide any conversion to **2f**. Changing the precatalyst to the 2‑aminobiphenylpalladium methanesulfonate dimer (**4**) in the presence of XPhos[26](#_ENREF_26) allowed for **2f** to be isolated in43% yield after only 3.5 hours at 40 °C (Scheme 4). This further exemplifies the utility of these mild reaction conditions for the late stage functionalisation of tetracarbonyl manganese(I) complexes based on a 2-phenyl-pyridine ligand backbone.



**Scheme 4.** Implementing a Suzuki-Miyaura cross-coupling with catalyst **4** and boronic acid **3** allows access to **2f** at 40 °C after only 3.5 hours.



**Figure 6.** CO release from a 40 µM solution of CO-RM **2f** using 50-60 µM myoglobin. Irradiation with LED (400 nm, 2.4 W). On for 2 min per 5 min period. \* indicates start of irradiation cycles.

Figure 6 shows a 40 µM assay of **2f**. This compound also shows stability in the dark, which is followed by a much slower release profile upon irradiation with the 400 nm LED. The slow, steady release of CO to myoglobin by **2f** may be related to the relatively low water solubility of this compound. In total, 1.0 eq. CO are released over the course of 102 min. Extending the assay time significantly is not practicable due to myoglobin degradation and CO escape.

Conclusions

A series of tetracarbonyl manganese(I) complexes based on a 2‑phenyl-pyridine system have been prepared in two linear steps in good yield. The manganese(I) complexes release CO efficiently on irradiation at both 365 nm and 400 nm. They are stable in solution until irradiation is initiated, *e.g.* stable to thermal degradation / reaction with sodium dithionite. Other reported photoCO-RMs are stable in water, although susceptible to deleterious interactions with sodium dithionite.[27](#_ENREF_27) PhotoCO-RMs **2a‑e** have been found to be thermally stable under the conditions of the myoglobin assay. However, **2f** displays a small amount of CO release in the dark.

Complex **2c** and **2d** were used at 10 µM concentrations in myoglobin assays and release three molecules of CO per CO-RM. The CO-RM can release the required CO at a lower concentration compared to, for example, CO-RM-3 which only releases one productive CO ligand.

It has been demonstrated that complex **2d** can be functionalised by direct a Pd-catalysed cross-coupling reaction to generate complexes **2e** and **2f**. Late-stage functionalisation of **2d** could be extended to improve water solubility, further conjugation to increase the wavelength of CO release, and fluorescent tagging for cell microscopy studies. All of these aspects are currently being examined within our laboratories.

Experimental Section

**General experimental details.** All reactions were carried out under a nitrogen atmosphere unless otherwise stated. Chemical reagents were purchased from Sigma Aldrich, Alfa Aesar or Frontier Scientific and used as received. All dry solvents apart from methanol were obtained from a Pure Solv MD-7 solvent machine and were stored in ampules under nitrogen until required. Ether solvents used in reactions came from the same machine but were deoxygenated by sonication with nitrogen bubbling for 30 minutes. All TLC analysis was carried out using Merck 5554 silica plates and spots were visualised using UV light at 254 and 365 nm. Column chromatography was carried out using silica 60 gel purchased from Sigma Aldrich. Solution 1H, and 13C NMR analysis was carried out on Jeol ESC400, ESX400 and ECX500 spectrometers. These were operating at 400 MHz (1H), 100 MHz (13C) frequencies for the appropriate experiments. 1H NMR spectra are reported in ppm(δ) and are referenced to the residual NMR solvent and were processed in MNova v.6 software. (CHCl3: 7.26 ppm DMSO: 2.54 ppm). All chemical shifts in reported 13C NMR spectra are reported in ppm (δ) and are referenced to the NMR solvent. (CHCl3: 77.36 ppm, DMSO: 40.45 ppm). In some instances, the complexes did not prove to be sufficinetly stable to permit observation of the metal carbonyl resonance in the 13C NMR spectrum. Mass Spectrometry was carried out using a Bruker microTOF instrument. All data was acquired in positive ion mode using ESI or LIFDI ionisation. High resolution spectrometry data is reported with less than 5 ppm error unless otherwise stated. All LIFDI data reported is within 120 ppm error. Melting points of all complexes and ligands were obtained on a Perkin Elmer DSC 7 machine. Experiments were all ran using a ramp rate of 10 °C min-1 to above the required melting temperature. The melting point was taken as the onset of the observed endothermic peak. IR spectra were taken using a Thermo-Nicolet Avatar-370 FT-IR spectrometer. Spectra were taken in either solid state (KBr Disc or ATR), or in solution using THF or methanol as solvents. UV-Visible spectroscopy for the myoglobin assay and molar absorption co-efficient determination was carried out on a JASCO V-560 spectrometer. A baseline in the required solvent was carried out prior to starting an assay. Photo-initiated carbon monoxide release was carried out using either a 365 nm 6W TLC lamp or a 5W 400 nm LED directly above the solution drawing 2.4 W of power. ABCat was prepared using a literature procedure by Fairlamb and co-workers.[20](#_ENREF_20) Pd(PPh3)4 was prepared using a literature procedure by Coulson and co-workers.[28](#_ENREF_28) 2‑Aminobiphenylpalladium methanesulfonate dimer (**4**) was prepared using a literature procedure by Buchwald and co-workers.[26](#_ENREF_26)

**General procedure 1 - synthesis of 2-(4-bromo-phenyl)pyridine (1d).**[**20**](#_ENREF_20)**,** [**28**](#_ENREF_28)**{Beeby, 2004 #1879}{Beeby, 2004 #1805}** In a nitrogen atmosphere glove box, to an oven dried Schlenk tube equipped with a magnetic stirrer was added Pd(PPh3)4 (0.02 eq., 0.033 mmol, 38.3 mg). The Schlenk tube was removed from the glove box and was attached to a Schlenk line. Under a high flow of nitrogen was added 4-bromobenzene boronic acid (1.5 eq., 2.5 mmol, 502 mg), followed by 2-bromopyridine (1 eq., 1.66 mmol, 158 µl/260 mg). 1.9M Na2CO3 (aq) (6 ml) and THF (9 ml) was then added via syringe. The reaction was heated to 60 °C for 64 h. The reaction was allowed to cool and deionised water (40 ml) was added. The product was extracted with dichloromethane (3 × 40 ml), dried with MgSO4 and filtered. The solvent was removed under reduced pressure to yield crude product. The crude product was purified using silica gel column chromatography using 90:10 PET ether/ethyl acetate as solvent. The solvent was removed to give a crystalline, slightly off white solid (231 mg, 59% Yield). MP (DSC): 64 °C ; 1H NMR (400 MHz, CDCl3) δ: 8.69 (dd, *J* = 4.8, 1.0 Hz, 1H), 7.88 (d, *J* = 8.3 Hz, 2H), 7.76 (td, *J =* 8.0, 1.0 Hz, 1H), 7.70 (dd, *J* = 8.0 Hz, 1.0 Hz, 1H), 7.60 (d, *J* = 8.3 Hz, 2H), 7.28–7.23 (m, 1H (under ref. Peak)); 13C NMR (100 MHz, CDCl3) δ: 156.6, 150.1, 138.5, 137.2, 132.2, 128.8, 123.8, 122.8, 120.7 ; Elemental Analysis (CHN) C : 56.15% H: 3.49% N: 5.77% (Calculated : C: 56.44% H: 3.34 % N: 5.98% ); ESI-MS m/z = 233.9917 [M+H]+ (calc. for C11NH9Br = 233.9913); IR (Pressed KBr disc) : 1581, 1556, 1458, 1426, 1389, 1147, 1095, 1066, 1001, 833, 772, 625, 539, 453 cm−1.

**2-(4-Fluoro-phenyl)pyridine (1b).**[**20**](#_ENREF_20)**,** [**28**](#_ENREF_28) **C**ompound **1e** was synthesised using general procedure 1using ABcat (0.007 eq., 11.6 µm, 12.2 mg), 4-fluorobenzeneboronic acid (1.5 eq., 2.5 mmol, 502 mg). The product was isolated as a slightly off white solid (226 mg, 79% Yield). Note: ABcat is air stable as a solid and doesn’t need to be weighed out in a glove box. 1H NMR (400MHz, CDCl3) δ: 8.67 (ddd, *J* = 4.8, 1.7, 1.0 Hz, 1H), 7.98 (dd, *J* = 9.0, 5.4 Hz 2H), 7.74 (td, *J =* 8.0, 1.7 Hz, 1H) , 7.67 (dt, *J =* 8.0, 1.0 Hz, 1H), 7.22 (ddd, *J* = 8.3, 4.8, 1.0 Hz, 2H), 7.15 (apr. t, *J* = 9.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: δ: 163.6 (d, *J* = 248.2 Hz), 156.7, 150.0, 137.1, 136.6 (d, *J* = 3.0 Hz), 128.8 (d, *J* = 8.5 Hz), 122.3, 121.1, 115.7 (d, *J* = 22.0 Hz); Elemental Analysis (CHN) C: 76.79% H: 4.71% N: 7.95%(Calculated : C: 76.29% H: 4.66% N: 8.09%) ESI-MS *m/z* = 174.0717[M+H]+ (calc. for C11NH9F = 174.0713).

**2-(4-Chloro-phenyl)pyridine (1c).**[**20**](#_ENREF_20)**,** [**28**](#_ENREF_28)Compound **1d** was synthesised using general procedure 1using 4-chlorobenzene boronic acid (1.5 eq., 2.5 mmol, 378 mg) and 2.0 M K2CO3(aq) (6 ml).The product was isolated as a crystalline, slightly off white solid (261 mg, 83% Yield). MP(DSC): 51°C ; 1H NMR (400 MHz, CDCl3) δ: 8.69 (dd, *J* = 4.6Hz, 0.7 Hz, 1H), 7.94 (d, *J* = 8.5 Hz, 2H), 7.76 (td, *J =* 8.0, 1.8 Hz, 1H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.44 (d, *J* = 8.5 Hz, 2H), 7.27-7.22 (m, 1H (under ref. peak)); 13C NMR (100 MHz, CDCl3) δ: 156.6, 150.1, 138.1, 137.2, 135.4, 129.3, 128.5, 122.8, 120.7; Elemental Analysis (CHN) C: 69.19% H: 4.30% N: 7.18%(Calculated : C: 69.67% H: 4.25% N: 7.39%)ESI-MS *m/z* = 190.0422[M+H]+ (calc. for C11NH9Cl = 190.0418); IR (Pressed KBr disc): 1585, 1565, 1491, 1462, 1433, 1397, 1153, 1087, 1009, 985, 847, 829, 773, 734, 702, 676, 633, 613, 541, 491, 452 cm−1.

**2-(Biphenyl)pyridine (1e).** [**20**](#_ENREF_20)**,** [**28**](#_ENREF_28)Compound **1e** was synthesised using general procedure 1(1.66 mmol of 2-bromopyridine)using biphenyl boronic acid (1.2 eq., 1.99 mmol, 331 mg). The product was isolated as a white solid (226 mg, 59% Yield). MP(DSC):144 °C;1H NMR (400 MHz, CDCl3) δ: 8.72 (dt, *J* = 4.7, 1.1 Hz, 1H), 8.09 (d, *J* = 8.5 Hz, 2H), 7.81–7.75 (m, 2H), 7.72 (d, *J =* 8.5 Hz, 2H), 7.67 (d, *J* = 8.0 Hz, 2H), 7.47 (t, *J* = 8.0 Hz, 2H), 7.37 (t, *J* = 7.3 Hz, 1H), 7.26–7.22 (m, 1H (under ref. peak)); 13C NMR (100 MHz, CDCl3) δ: 157.4, 150.1, 142.1, 141.0, 138.7, 137.1 129.2, 127.9, 127.8, 127.6, 127.5, 122.5, 120.9; Elemental Analysis (CHN): C: 87.84% H: 5.75% N: 5.92% (Calculated: C: 88.28% H: 5.67% N: 6.06%) ESI-MS *m/z* = 232.1122[M+H]+ (calc. for C17NH14= 232.1120); IR (Pressed KBr disc): 1603, 1595, 1584, 1570, 1556, 1487, 1464, 1448, 1430, 1400, 1296, 1181, 1149, 1058, 1035, 1003, 983, 906, 847, 786, 752, 711, 687, 644, 625, 608, 452 cm−1.

**Benzyl pentacarbonyl manganeseI. ­**[**29**](#_ENREF_29)To an oven-dried Schlenk tube equipped with a magnetic stirrer under nitrogen was added mercury (3 cm3). Sodium metal (4 eq., 1.07 mmol, 246 mg) was added in small pieces with high stirring to allow dissolution. In a separate Schlenk tube under nitrogen was added Mn2(CO)10 (1 eq., 2.68 mmol, 1.04 g), followed by anhydrous, deoxygenated THF (40 ml). The THF solution was then transferred by cannula on to the sodium amalgam and was stirred for 3 hours. In a separate Schlenk tube equipped with a magnetic stirrer under nitrogen was added benzyl chloride (2 eq., 5.36 mmol, 617 µl / 678 mg). The Schlenk tube containing benzyl chloride was placed in an ice bath and put under vacuum with stirring for 60 seconds. At ambient temperature, the THF solution of NaMn(CO)5 was transferred by cannula into the benzyl chloride. The mixture was stirred at ambient temperature (20 °C) for 20 h. The solution was then filtered through a bed of Celite™ and was washed with diethyl ether (5 × 20 ml). The contents were then loaded on to silica gel and this was added on to a pad of silica (5 cm). The pad was washed with petroleum ether (3 × 40 ml). The solvent was removed to yield product contaminated with benzyl chloride. Benzyl chloride was removed at 35 °C under vacuum. The product must be broken up periodically with a spatula and put back under vacuum. A slightly yellow crystalline product was obtained. (1.18 g, 76% yield). MP (DSC): 40 °C; 1H NMR (400 MHz, CDCl3); δ: 7.18 (m, 4H), 6.97(m, 1H), 2.41 (s, 2H). IR (solution THF): 2107, 2047, 2009, 1987 cm-1; ESI-MS *m/z:* 286.9748 [M+H]+ (Calculated for MnO5C12H8 : 286.9747).

**General procedure 2 - Synthesis of Tetracarbonyl (2-phenylpyridine-κ2N,C8)manganeseI (2a).**[**30**](#_ENREF_30)**,** [**31**](#_ENREF_31)To an oven dried Schlenk tube equipped with a magnetic stirrer under nitrogen was added 2-phenylpyridine (1 eq., 1 mmol, 143 µl/ 155 mg), BnMn(CO)5 (1 eq., 1 mmol, 286 mg) followed by dry deoxygenated *n*-hexane (16 ml). The mixture was heated with stirring for 6 h. The reaction mixture was allowed to cool to ambient temperature. The hexane solution was filtered through a pipette packed with cotton wool and removal of solvent under reduced pressure yielded a pure yellow crystalline solid (284 mg, 88% Yield). MP(DSC) : 114 °C; 1H NMR (400 MHz, CDCl3) δ: 8.72 (d, *J* = 5.5Hz, 1H), 7.97 (d, *J* = 7.5Hz, 1H), 7.87 (d, *J* = 8.1Hz, 1H), 7.81–7.74 (m, 2H), 7.28 (td, *J* = 7.5, 1.0 Hz, 1H), 7.17 (td, *J* = 7.5, 1.5 Hz, 1H), 7.11 (ddd, *J* = 7.5, 5.5, 1.5 Hz, 1H): 13C NMR (100 MHz, CDCl3) δ: 174.9, 166.4, 153.9, 146.2, 141.7, 137.9, 130.3 124.2, 124.0, 122.4, 119.3. Elemental Analysis (CHN): C: 56.65% H: 2.98% N: 4.06% (Calculated: C: 56.10% H: 2.51% N: 4.36% LIFDI-MS *m/z* = 321.0202[M]+ (calc. for MnC15H8NO4 = 320.9834). IR (Solution: THF): 2071, 1986, 1972, 1928, 1600, 1576, 1477 cm −1.

**Tetracarbonyl (2-(4-fluoro-phen)κ,C2­-pyridine-κ,N)ManganeseI (2b),** Using the details from general procedure **2**, BnMn(CO)5 (1 eq., 0.5 mmol, 143 mg), 2-(4-fluoro-phen-4-yl)pyridine (1 eq., 0.5 mmol, 86.5 mg) and *n*-hexane (8 ml) were used to prepare complex **2b**. After 6 h, the reaction mixture was allowed to cool to ambient temperature. CH2Cl2 (10 ml) was added to dissolve the yellow precipitate. The mixture was filtered through cotton wool and solvent was removed under reduced pressure to yield product containing 20% starting material (**1b**). The impure product was reacted with more BnMn(CO)5 (0.2 eq.) at 75 °C in hexane for six hours. Addition of dichloromethane and filtration as previously mentioned yielded a pure yellow solid (74 mg , 43% Yield). MP(DSC): 163 °C; 1H NMR (400 MHz, CDCl3) δ: 8.69 (dt, *J* = 5.6, 1.2 Hz, 1H), 7.87–7.78 (m, 2H), 7.75 (dd, *J* = 8.5, 5.1 Hz, 1H), 7.68 (dd, *J* = 8.5, 2.5 Hz, 1H), 7.06–7.15(m, 1H), 6.84 (td, *J* = 8.5, 2.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 179.6, 165.7, 163.6 (d, *J* = 256.0 Hz), 154.2, 142.4, 138.3, 127.0 (d, *J* = 18.0 Hz), 125.22 (d, *J* = 8.5 Hz), 122.5, 119.5, 111.3 (d, J = 23.0 Hz); Elemental Analysis (CHN) C: 52.94% H: 2.21% N: 3.98% (Calculated: C: 53.12% H: 2.08% N: 4.13%) ESI-MS *m/z* = 339.9827[M+H]+ (calc. for MnC15H8FNO4= 339.9812). IR (Solution: THF): 2075, 1993, 1977, 1936, 1605, 1587, 1571, 1558, 1480, 1464, 1431, 1315, 1262, 1192 cm−1.

**Tetracarbonyl (2-(4-chloro-phenyl)κ,C2­-pyridine-κ,N)manganeseI (2c).** Using the details from general procedure **2**, BnMn(CO)5 (1 eq., 0.25 mmol, 72 mg), 2-(4-chloro-phenyl)pyridine(**1c**)(1 eq., 0.25 mmol, 50 mg) and *n*-hexane (4 ml) were used to prepare complex **2c**. At the end of the reaction, the reaction mixture was allowed to cool to ambient temperature. Dichloromethane (5 ml) was added to the mixture to dissolve the yellow precipitate. The solution was filtered through cotton wool packed in a pipette. Removal of solvent under reduced pressure gave pure product (82 mg, 83% Yield). MP (DSC): 161 °C; 1H NMR (400 MHz, CDCl3) δ: 8.71 (d, *J* = 4.3 Hz, 1H), 7.93 (s, 1H), 7.85–7.78 (m, 2H), 7.68 (d, *J* = 8.0 Hz, 1H), 7.15(d, *J =* 6.5 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ: 178.2, 165.7, 154.2, 144.7, 140.7, 138.4, 136.8, 125.1, 124.6, 122.9, 119.7. Elemental Analysis (CHN) C: 50.53% H: 2.11% N: 3.72% (Calculated: C: 50.66% H: 1.98% N: 3.94%) LIFDI-MS *m/z* = 354.9831[M]+ (calc. for MnC15H7ClNO4= 354.9444). IR (Solution: THF): 2077, 1993, 1978, 1936, 1605, 1567, 1543, 1478, 1424 cm−1.

**Tetracarbonyl (2-(4-bromo-phenyl)κ,C2­-pyridine-κ,N)manganeseI (2d).** Using the details from general procedure **2**, BnMn(CO)5 (1 eq., 0.75 mmol, 215 mg), 2-(4-bromo-phenyl)pyridine (1 eq., 0.75 mmol, 176 mg) and *n*-hexane (12 ml) were used to prepare complex **2d**. At the end of the reaction, the Schlenk tube was stored in the freezer (−18 °C) overnight. The product had precipitated out of solution and the hexane solution was removed with a pipette. The yellow/brown solid product was then dried under reduced pressure. (217 mg, 72% Yield).

MP (DSC): 208 °C; 1H NMR (400 MHz, CDCl3) δ: 8.71 (d, *J* = 5.6, 1H), 8.09 (d, *J* = 1.9Hz, 1H), 7.88–7.78 (m, 2H), 7.61(d, *J* = 8.5 Hz, 1H), 7.31 (dd, *J =* 8.5, 2.0 Hz, 1H), 7.15 (d, *J* = 6.7, 2.1 Hz, 1H); 13C NMR (126 MHz CDCl3) δ: 219.5, 214.0, 213.2, 178.6, 165.6, 154.0, 144.8, 143.3, 138.1, 127.2, 126.1, 125.1, 122.8, 119.5. Elemental Analysis (CHN) C: 44.97% H: 1.75% N: 3.39% (Calculated: C: 45.03% H: 1.76% N: 3.50%) ESI-MS *m/z* = 399.9017[M+H]+ (calc. for MnC15H8BrNO4= 399.9012). IR (Solution: THF): 2075, 1992, 1977, 1936, 1259 cm−1.

**Tetracarbonyl (2‑(biphenyl)κ,C2‑pyridine‑κ,N)manganeseI (2e).** Using the details from general procedure 2, compound **3**, BnMn(CO)5 (1 eq., 0.5 mmol, 143 mg), 2-(biphenyl)pyridine (1 eq., 0.5 mmol, 116 mg) and *n*-hexane (8 ml) were used to prepare complex **2e**. At the end of the reaction, the reaction mixture was allowed to cool to ambient temperature. Dichloromethane (10 ml) was added to the mixture to dissolve the yellow precipitate. The solution was filtered through cotton wool packed in a pipette. Removal of solvent under reduced pressure gave pure product (144 mg, 72% Yield). MP(DSC): 138 °C; 1H NMR (400 MHz, CDCl3) δ: 8.74 (ddd, *J* = 6.0, 1.7, 1.0 Hz, 1H), 8.21 (d, *J* = 1.8 Hz, 1H), 7.91 (d, *J =*  8.0 Hz, 1H), 7.85 (d, *J =*  8.0 Hz, 1H), 7.83–7.77 (m, 1H), 7.77–7.70 (m, 2H), 7.48 (t, *J = 7*.6 Hz, 2H), 7.42 (dd *J* = 8.0, 1.8 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.13 (ddd, *J* = 7.5, 6.0, 1.4 Hz, 1H) ; 13C NMR (100 MHz, CDCl3) δ: 175.6, 166.4, 154.2, 154.6, 142.8, 141.7, 140.2, 138.2, 129.1, 127.8, 124.6, 123.6, 122.6, 119.7; Elemental Analysis (CHN) C: 63.61 % H: 3.44 % N: 3.39 % (Calculated: C: 63.49% H: 3.04% N: 3.53% ); LIFDI-MS *m/z* = 397.0349[M]+ (calc. for MnC21H12NO4 = 397.0147). IR (Solution: THF): 2073, 1989, 1974, 1932, 1602, 1582, 1562, 1477, 1475 cm−1.

**Alternative synthesis of complex 2e *via* a cross-coupling reaction.** This synthesis is based on a modified literature procedure.[25](#_ENREF_25) **Precatalyst solution**: To a dry Schlenk tube was added Pd(OAc)2 (1.0 eq., 22 µmol, 5 mg) and XPhos (2.0 eq., 45µmol, 21.2 mg) under a high flow of nitrogen. Dry, degassed THF (1 ml) was added to make a red stock solution of catalyst/ligand.

To a dry Schlenk tube equipped with a magnetic stirrer bar was added complex **2d** (1 eq., 0.125 mmol, 50 mg), phenyl boronic acid (1.5 eq., 0.188 mmol, 23 mg) and K3PO4 ( 2.0 eq., 0.250 mmol, 34 mg). The Schlenk tube was evacuated and backfilled with N2 three times. Dry degassed toluene (1 ml) was added to the Schlenk tube and the contents were stirred for 5 minutes at ambient temperature. Catalyst stock solution (60 µl) giving Pd(OAc)2 (1 mol%, 0.3 mg) and Xphos (2 mol%, 1.2 mg) was added *via* syringe to the Schlenk tube. The reaction mixture was then heated to 50 °C with vigorous stirring in the dark for 23 h. The reaction was quenched by cooling to ambient temperature. This was then filtered through a pipette packed with Celite™ and subsequently filtered through a silica plug in a pipette eluting with toluene collecting small fractions. Solvent was then removed under reduced pressure to give crude product. The crude mixture was purified by silica gel column chromatography. It was loaded on to silica using CH2Cl2, and then was charged on to a column packed with 5% EtOAc: pet ether. The product was eluted by switching to 10% and finally 15% EtOAc:Pet ether. Removal of column solvent under reduced pressure gave product **2e** as an off white solid (32 mg, 67% yield).

**Tetracarbonyl (2-(4-morpholinocarbonyl) biphenyl)κ,C2­-pyridine-κ,N)manganeseI (2f).** This synthesis is based on a modified literature procedure.[32](#_ENREF_32) **Precatalyst solution**: A dried schlenk tube equipped with a magnetic stirrer bar was charged with 2‑Aminobiphenylpalladium methanesulfonate dimer (**4**) (1.0 eq., 0.01 mmol, 7.4 mg) and ligand (2.0 eq., 0.02 mmol, 9.5 mg). This tube was evacuated and refilled with N2 three times. THF (1 ml) was then added and the colourless solution was allowed to age for thirty minutes with stirring at room temperature before use in the coupling reaction. No colour change was observed.

**Suzuki-Miyaura Coupling of Tetracarbonyl (2‑(4‑bromo‑phenyl)κ,C2­-pyridine-κ,N)manganeseI (2d) with 4‑morphoninocarbonylphenyl boronic acid (3)**: The 0.5 M K3PO4 solution was prepared by dissolving K3PO4 (10.6 g, 50 mmol) in deionized water (100 ml) and degassed by performing several evacuation/N2 refill cycles (until bubbling stops) under sonication prior to use. A dry Schlenk tube equipped with a magnetic stirrer bar and Teflon septum was charged with 3 (1.5 eq., 0.188 mmol, 44 mg) and **2d** (1.0 eq., 0.126 mmol, 50 mg). It was then evacuated and refilled with N2 three times and the aged precatalyst solution in THF (314 µl, 5 mol % Pd) and aqueous K3PO4 (2.0 eq., 1.0 mmol, 0.5 M, 2.00 ml) were added by syringe. The reaction was stirred at 40 °C for 3.5 hours, after which it was opened to air and passed through a small plug of celite. The solvent was removed under reduced pressure and the crude mixture purified by silica gel column chromatography. It was loaded onto silica using CH2Cl2, and then was charged onto a column packed with 80% EtOAc: pet ether. The product was eluted with 80% EtOAc: pet ether. Removal of the solvent under reduced pressure provided the product as a white solid (28 mg, 43% yield). MP: 146–148°C (dec); 1H NMR (400 MHz, CD2Cl2) δ: 8.73 (d, *J* = 5.7 Hz, 1H), 8.18 (d, *J* = 1.8 Hz, 1H), 7.93 (d, *J* = 8.1 Hz, 1H), 7.88 (d, *J* = 8.1 Hz, 1H), 7.86–7.80 (m, 1H), 7.76 (d, *J* = 7.6 Hz, 2H), 7.48 (d, *J* = 7.6 Hz, 2H), 7.43 (dd, *J* = 8.1, 1.8 Hz, 1H), 7.41 – 7.33 (m, 2H), 7.15 (ddd, *J* = 7.2, 5.7, 1.3 Hz, 1H), 3.39-3.30 (m, 8H); 13C NMR (100 MHz, CD2Cl2) δ: 175.4, 165.7, 154.1, 146.1, 142.8, 141.3, 139.6, 138.1, 129.7, 128.5, 127.7, 127.3, 127.1, 124.3, 123.2, 122.8, 119.6, 66.9, 66.8; Elemental Analysis (CHN) C: 61.30% H: 3.70 % N: 5.72% (Calculated: C: 61.19% H: 3.75% N: 5.59%); LIFDI‑MS *m/z* = 510.06[M]+ (calc. for MnC26H19N2O6= 510.0624); ESI-MS *m/z* = 511.0705 [M+H]+ (calc. for MnC26H20N2O6= 511.0696), 533.0509 [M+Na]+ (calc for MnC26H19N2NaO6= 533.0516). IR (ATR): 2855, 2072, 1965, 1922, 1629, 1603, 1580, 1561, 1474, 1456, 1427, 1277, 1257, 1114, 1010, 954, 784, 763, 675, 6454, 550, 438 cm−1.

**Myoglobin assay for determining CO-release rates.** The procedure was carried out as previously described,[14](#_ENREF_14) taking into consideration the precautions noted by McLean *et al.*.[27](#_ENREF_27)

Acknowledgments

We would like to thank BBSRC and the Wellcome Trust for funding. We would also like to acknowledge Dr. A.-K. Duhme-Klair for discussions related to the parent phenylpyridine manganese(I) complex.

References

1. R. Motterlini and L. E. Otterbein, *Nat. Rev. Drug. Discov.*, **2010**, 9, 728-43.

2. B. E. Mann, *Organometallics*, **2012**, 31, 5728-35.

3. S. Rattan, R. A. Haj and M. A. F. De Godoy, *Am. J. Physiol-Gastr. L.*, **2004**, 287, G605-G11.

4. L. S. Nobre, J. D. Seixas, C. C. Romao and L. M. Saraiva, *Antimicrob. Agents Ch.*, **2007**, 51, 4303-07.

5. M. Desmard, K. S. Davidge, O. Bouvet, D. Morin, D. Roux, R. Foresti, J. D. Ricard, E. Denamur, R. K. Poole, P. Montravers, R. Motterlini and J. Boczkowski, *FASEB J.*, **2009**, 23, 1023-31.

6. R. Foresti, M. G. Bani-Hani and R. Motterlini, *Intens. Care Med.*, **2008**, 34, 649-58.

7. H. Pfeiffer, T. Sowik and U. Schatzschneider, *J. Organomet. Chem.*, **2013**, 734, 17-24.

8. A. J. Atkin, I. J. S. Fairlamb, J. S. Ward and J. M. Lynam, *Organometallics*, **2012**, 31, 5894-902.

9. G. J. L. Bernardes, T. Santos-Silva, A. Mukhopadhyay, J. D. Seixas, C. C. Romao and M. J. Romao, *J. Am. Chem. Soc.*, **2011**, 133, 1192-95.

10. S. H. Crook, B. E. Mann, A. J. Meijer, H. Adams, P. Sawle, D. Scapens and R. Motterlini, *Dalton Trans.*, **2011**, 40, 4230-5.

11. J. Niesel, A. Pinto, H. W. Peindy N'Dongo, K. Merz, I. Ott, R. Gust and U. Schatzschneider, *Chem. Commun.*, **2008**, DOI: 10.1039/b719075a, 1798-800.

12. F. Mohr, J. Niesel, U. Schatzschneider and C. W. Lehmann, *Z. Anorg. Allg. Chem.*, **2012**, 638, 543-46.

13. H. Pfeiffer, A. Rojas, J. Niesel and U. Schatzschneider, *Dalton Trans.*, **2009**, DOI: 10.1039/b819091g, 4292-8.

14. J. S. Ward, J. M. Lynam, J. W. B. Moir, D. E. Sanin, A. P. Mountford and I. J. S. Fairlamb, *Dalton Trans.*, **2012**, 41, 10514-17.

15. S. J. Carrington, I. Chakraborty and P. K. Mascharak, *Chem. Commun.*, **2013**, 49, 11254-6.

16. I. Chakraborty, S. J. Carrington and P. K. Mascharak, *Acc. Chem. Res.*, **2014**, 47, 2603-11.

17. M. A. Gonzalez, N. L. Fry, R. Burt, R. Davda, A. Hobbs and P. K. Mascharak, *Inorg. Chem.*, **2011**, 50, 3127-34.

18. M. A. Gonzalez, M. A. Yim, S. Cheng, A. Moyes, A. J. Hobbs and P. K. Mascharak, *Inorg. Chem.*, **2012**, 51, 601-08.

19. M. I. Bruce, B. L. Goodall and I. Matsuda, *Aust. J. Chem.*, **1975**, 28, 1259-64.

20. A. Beeby, S. Bettington, I. J. S. Fairlamb, A. E. Goeta, A. R. Kapdi, E. H. Niemela and A. L. Thompson, *New. J. Chem.*, **2004**, 28, 600-05.

21. R. L. Bennett, M. I. Bruce and I. Matsuda, *Aust. J. Chem.*, **1975**, 28, 1265-72.

22. R. Motterlini, J. E. Clark, R. Foresti, P. Sarathchandra, B. E. Mann and C. J. Green, *Circ. Res.*, **2002**, 90, E17-24.

23. I. J. S. Fairlamb, S. M. Syvanne and A. C. Whitwood, *Synlett*, **2003**, 1693-97.

24. P. Ricci, K. Krämer and I. Larrosa, *J. Am. Chem. Soc.*, **2014**, 136, 18082-86.

25. S. D. Walker, T. E. Barder, J. R. Martinelli and S. L. Buchwald, *Angew. Chem. Int. Ed.*, **2004**, 43, 1871-76.

26. N. C. Bruno, M. T. Tudge and S. L. Buchwald, *Chemical Science*, **2013**, 4, 916-20.

27. S. McLean, B. E. Mann and R. K. Poole, *Anal. Biochem.*, **2012**, 427, 36-40.

28. D. R. Coulson, L. C. Satek and S. O. Grim, *Inorg. Syn.*, **1972**, 13, 121-23.

29. M. Bruce, M. Liddel and G. Pain, *Inorg. Syn.*, **1989**, 26, 171-72.

30. M. Pfeffer, J. P. Djukic and A. Maisse, *J. Organomet. Chem.*, **1998**, 567, 65-74.

31. J. P. Djukic, K. H. Dotz, M. Pfeffer, A. DeCian and J. Fischer, *Organometallics*, **1997**, 16, 5171-82.

32. T. D. Senecal, W. Shu and S. L. Buchwald, *Angew. Chem. Int. Ed.*, **2013**, 52, 10035-39.

.

Received: ((will be filled in by the editorial staff))  
Published online: ((will be filled in by the editorial staff))

°

**Entry for the Table of Contents** (Please choose one layout)

**Layout 1:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | | | Key Topic |
| Photoactivated CO-releasing molecules have been traditionally irradiated using a TLC lamp. In this paper the use of LEDs close to the sample is reported. This gives efficient CO release compared to a TLC lamp with much smoother kinetic data. The complex shown releases CO efficiently and can be functionalised further with a Suzuki reaction. |  |  |  | Jonathan S. Ward, Joshua T. W. Bray, Conrad Wagner, James W. B. Moir, Jason M. Lynam\*, and Ian J. S. Fairlamb\*…….. Page No. – Page No.  Photoactivated functionizable CO-releasing molecules based on manganese(I):Palladium-catalysed Suzuki cross coupling reaction on a  CO-RM  Keywords: Carbon monoxide/ CO-releasing molecules/CO-RM /morpholine/Suzuki–Miyaura |

Supporting Information

((Please insert the Supporting Information here and submit the CIF and CheckCIF files for all new compounds by e-mail to [EurJIC@wiley-vch.de](mailto:EurJIC@wiley-vch.de)))